share_log

Oppenheimer Reiterates Outperform on Corbus Pharmaceuticals, Maintains $22 Price Target

Oppenheimer Reiterates Outperform on Corbus Pharmaceuticals, Maintains $22 Price Target

奥本海默重申Corbus Pharmicals的表现跑赢大盘,维持22美元的目标股价
Benzinga ·  2023/08/09 09:47

Oppenheimer analyst Jeff Jones reiterates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and maintains $22 price target.

奥本海默分析师杰夫·琼斯重申了Corbus Pharmicals(纳斯达克股票代码:CRBP)的表现跑赢大盘,并维持22美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发